Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease

Cancer Research

Volumn 60, Issue 20, 2000, Pages 5797-5802

  Anderson L D , Jr ^a   Mori, S ^a   Mann, S ^a   Savary, C A ^a   Mullen, C A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN; NUCLEOPROTEIN; TUMOR ANTIGEN; TUMOR VACCINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR; FEMALE; FIBROSARCOMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; HISTOPATHOLOGY; IMMUNIZATION; LUNG TUMOR; LYMPHOMA CELL LINE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, NEOPLASM; BONE MARROW TRANSPLANTATION; CANCER VACCINES; EPITOPES; FEMALE; FIBROSARCOMA; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; INFLUENZA VACCINES; LUNG NEOPLASMS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASM TRANSPLANTATION; NUCLEOPROTEINS; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL CORE PROTEINS;

EID: 0034667391     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
2. Multiple cancers. Tumor burden permits the outgrowth of other cancers
3. Lymphocyte depletion during treatment with intensive chemotherapy for cancer
4. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy
5. Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy
6. Graft-versus-leukemia reactions after bone marrow transplantation
7. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
8. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
9. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine
10. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease
11. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease
12. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities
13. Tumor antigens recognized by T cells
14. Cancer vaccines based on the identification of genes encoding cancer regression antigens
15. Human tumor antigens recognized by T cells
16. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines
17. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens
18. Cloning and expression of influenza virus genes
19. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses
20. Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes
21. Cytotoxic T cells recognize fragments of the influenza nucleoprotein
22. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response
23. Improved retroviral vectors for gene transfer and expression
24. Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis
25. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation
26. Immune selection after antigen-specific immunotherapy of melanoma
27. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immuno-suppression
28. Cytokine dysregulation and acute graft-versus-host disease
29. Restricted TCR repertoire and long-term persistence of donor-derived antigen-experienced CD4+ T cells in allogeneic bone marrow transplantation recipients
30. HER-2/neu oncogenic protein: Issues in vaccine development
31. Tumor antigens recognized by T lymphocytes
32. The immunology and immunotherapy of breast cancer: An update
33. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
34. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study
35. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy